Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Lovaza · 1 trial · 1 indication
Primary Specific Aim To determine the effects of omega-3 fatty acid supplementation on urine protein excretion and surrogate markers of kidney injury including: serum beta-microglobulin and cystatin C (biomarkers of GFR) and urine neutrophil gelatinase-associated lipocain (NGAL a.k.a. lipocalin-2), kidney injury molecule-1 (KIM-1), and interleukin-18 (IL-18) (biomarkers of tubular reabsorption impairment and inflammation).
| Arm | Type | Description |
|---|---|---|
| Lovaza | EXPERIMENTAL | 4 grams per day |
| Name | Type | Description |
|---|---|---|
| Lovaza (fish oil) | DIETARY_SUPPLEMENT | 4 grams per day |
Inclusion Criteria: * Participants have a diagnosis of diabetes (either oral medication or diet controlled) * Have an average systolic blood pressure (SBP) \<150 and diastolic blood pressure (DBP) \<90 mmHg * Have quantified proteinuria -- urine albumin/creatinine ratio of \> 17 mg/g (men) and \>25...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| FibroBiologics, Inc. | FBLG | 1 | PHASE1 | Undisclosed |
| MiMedx Group, Inc. | MDXG | 2 | N/A | Undisclosed |
| Integra LifeSciences Holdings Corporation | IART | 1 | N/A | Undisclosed |
| Organogenesis Holdings, Inc. Class A | ORGO | 1 | N/A | Undisclosed |
| Healthcare Services Group, Inc. | HCSG | 1 | N/A | Undisclosed |
Lovaza is an investigational omega-3 fatty acid supplement being studied for use in diabetes, specifically for diabetes-related kidney disease. It is in Phase 3 clinical development. The drug is being evaluated for its potential effects on kidney health in patients with diabetes.
Lovaza is being developed by GSK plc, a global biopharmaceutical company. GSK trades on the stock exchange under the ticker symbol GSK. The company is conducting clinical research to evaluate Lovaza's safety and efficacy for diabetes-related kidney disease.
Lovaza is in Phase 3 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. The Phase 3 trial for Lovaza has been completed, and the drug is still undergoing clinical evaluation for its potential use in diabetes.
Lovaza has one completed Phase 3 clinical trial registered under NCT01092390, titled "Go Fish: Omega-3 Fatty Acid Supplementation in Diabetes-Related Kidney Disease." The trial enrolled 31 participants in the United States and was a randomized, double-blind study without a control group.
Lovaza is an omega-3 fatty acid supplement. It is being studied for its potential benefits in diabetes-related kidney disease. The drug is a formulation of omega-3 fatty acids, which are commonly found in fish oil. Lovaza is currently in Phase 3 clinical development for this indication.